WARNING: DRUG-DRUG INTERACTIONS LEADING TO POTENTIALLY SERIOUS AND/OR LIFE THREATENING REACTIONS
Co-administration of NORVIR with several classes of drugs including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations may result in potentially serious and/or life-threatening adverse events due to possible effects of NORVIR on the hepatic metabolism of certain drugs. Review medications taken by patients prior to prescribing NORVIR or when prescribing other medications to patients already taking NORVIR [see Contraindications (4)
, Warnings and Precautions
, Drug Interactions (7)
, and Clinical Pharmacology ].
Media Articles Related to Norvir (Ritonavir)
Efficacy of DRV/r Monotherapy vs DRV/r With Two NRTIs
Source: Medscape HIV/AIDS Headlines [2017.01.11]
How does darunavir/ritonavir monotherapy compare with DRV/r-based triple ART in terms of efficacy and safety?
Published Studies Related to Norvir (Ritonavir)
Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir. [2011.09]
OBJECTIVES: Treatment of HIV/tuberculosis (TB) co-infected patients is complex due to drug-drug interactions for these chronic diseases. This study evaluates an intermittent dosing regimen for rifabutin when it is co-administered with ritonavir-boosted atazanavir... CONCLUSIONS: The benefits to HIV/TB co-infected patients receiving rifabutin 150 mg three times weekly or every other day may outweigh the risks of neutropenia observed here in non-HIV-infected subjects, provided that patients on combination therapy will be closely monitored for safety and tolerability.
96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline. [2011.08]
BACKGROUND: In virologically suppressed patients, switching to darunavir/ritonavir monotherapy could avoid resistance and adverse events from continuing nucleoside analogues. METHODS: Two hundred and fifty-six patients with HIV RNA <50 copies/mL on current antiretrovirals were switched to darunavir/ritonavir 800/100 mg once daily, either as monotherapy (n = 127) or with two nucleoside analogues (n = 129)...
Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. [2011.07.15]
BACKGROUND: We compare the effect of 4 different antiretroviral regimens on limb and visceral fat... CONCLUSIONS: ABC-3TC- and TDF-FTC-based regimens increased limb and visceral fat at week 96, with a similar prevalence of lipoatrophy. Compared to the EFV group, subjects assigned to ATV-r had a trend towards higher mean percentage increase in VAT. CLINICAL TRIALS REGISTRATION: NCT00118898.
Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir. [2011.07]
Dolutegravir (DTG) is an unboosted, once-daily integrase inhibitor currently in phase 3 trials. Two studies evaluated the effects of etravirine (ETR) alone and in combination with ritonavir (RTV)-boosted protease inhibitors (PIs) on DTG pharmacokinetics (PK) in healthy subjects... The combination of DTG and ETR alone should be avoided; however, DTG may be coadministered with ETR without a dosage adjustment if LPV/RTV or DRV/RTV is concurrently administered.
Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naive HIV-1-infected patients (the ARTEN study). [2011.07]
OBJECTIVES: Dyslipidaemic effects of antiretrovirals (ARVs) may contribute to increased cardiovascular risk (CR) in HIV-1-infected patients. The ARTEN (atazanavir/ritonavir on a background of tenofovir and emtricitabine vs. nevirapine on the same background, in naive HIV-1-infected patients) study compared prospectively ritonavir-boosted atazanavir (ATZ/r) 300 mg/100 mg once daily (qd) with immediate release nevirapine (NVP) 200 mg twice daily or 400 mg qd, each combined with fixed-dose tenofovir 300 mg/emtricitabine 200 mg qd in 569 ARV-naive HIV-1-infected patients. Lipid profiles and CR from baseline to week 48 are reported... CONCLUSIONS: In ARV-naive patients with low CR at the outset, NVP showed a potentially less atherogenic lipid profile compared with ATZ/r. (c) 2011 British HIV Association.
Clinical Trials Related to Norvir (Ritonavir)
Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected Individuals [Recruiting]
The purpose of this study is to assess whether a boosting by cobicistat results in similar
concentrations of darunavir in the brain compared to a boosting by ritonavir.
Bioequivalence Study of Generic GPO Ritonavir Versus Norvir´┐Ż [Completed]
To establish bioequivalence of ritonavir generic capsule, with Norvir« as reference drug.
Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study [Active, not recruiting]
Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected Subjects [Completed]
The study aims to help us understand if the HIV drugs darunavir (taken with ritonavir) and
raltegravir will affect each other when they are given at the same time.
The purpose of the study is to assess the pharmacokinetics (how a drug is absorbed,
distributed and eliminated from your body) of darunavir and ritonavir when these are taken
with and without raltegravir.
The duration of the study will be up to 50 days plus a screening visit which will take place
up to 4 weeks prior to the start of the study, and a follow up visit which takes place 1-2
weeks after the last dose of study medication.
Subjects will continue to take 2 of their usual drugs (those called nucleoside reverse
transcriptase inhibitors - NRTI) throughout the study.
For the first 21 days subjects will take their usual NRTI plus raltegravir 400mg twice
daily. After this, subjects will also receive either:
Group 1) Darunavir/ritonavir 800mg/100mg once daily AND raltegravir 400mg twice daily or
Group 2) Darunavir/ritonavir 800mg/100mg once daily AND raltegravir 800mg once daily
Subjects will take this regimen for 14 days. Subjects will be randomly allocated to either
Group 1 or 2. You will have an equal (50/50) chance of being allocated to Group 1 or 2.
Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin [Completed]
Pravastatin (Pravachol) is approved by the Food and Drug Administration (FDA) and is used to
treat high cholesterol. Darunavir (Prezista) and ritonavir (Norvir) are approved by the
Food and Drug Administration (FDA) to treat HIV infection. When darunavir and ritonavir are
given with pravastatin, they can increase the blood levels of pravastatin. The degree of
this interaction varies from person to person. The way that darunavir and ritonavir
interact with pravastatin may be affected by a person's genetic make-up. Genetic factors
(or DNA) are those that people are born with and that make each person unique. Genetic
differences are the reason why one person's body traits such as height and hair color are
different from another person's body traits. Genetic differences can also affect the way a
medication works in the body or the way two medications interact in the body. The purpose
of this clinical study is to determine if a person's genetic make-up affects the way
darunavir and ritonavir interact with pravastatin in the body.
Reports of Suspected Norvir (Ritonavir) Side Effects
Foetal Exposure During Pregnancy (128),
Maternal Exposure During Pregnancy (66),
Abortion Spontaneous (57),
Renal Failure Acute (45),
Premature Baby (39),
Abortion Induced (35),
Drug Interaction (28),
Anaemia (26), more >>